Active 0 6 0 6 O
hepatitis 7 16 7 16 B-chronic_disease
B 17 18 17 18 I-chronic_disease
or 19 21 19 21 O
hepatitis 22 31 22 31 B-chronic_disease
C 32 33 32 33 I-chronic_disease
with 34 38 34 38 O
abnormal 39 47 39 47 O
liver 48 53 48 53 O
function 54 62 54 62 O
tests 63 68 63 68 O

Active 0 6 69 75 B-chronic_disease
liver 7 12 76 81 I-chronic_disease
disease 13 20 82 89 I-chronic_disease
from 21 25 90 94 O
autoimmune 26 36 95 105 B-chronic_disease
disorders 37 46 106 115 I-chronic_disease
or 47 49 116 118 O
sclerosing 50 60 119 129 B-chronic_disease
cholangitis 61 72 130 141 I-chronic_disease

Any 0 3 142 145 O
predisposing 4 16 146 158 O
chronic 17 24 159 166 O
condition 25 34 167 176 O
resulting 35 44 177 186 O
in 45 47 187 189 O
baseline 48 56 190 198 O
grade 57 62 199 204 B-lower_bound
2 63 64 205 206 I-lower_bound
or 65 67 207 209 O
higher 68 74 210 216 O
diarrhea 75 83 217 225 B-chronic_disease

Any 0 3 226 229 O
prior 4 9 230 235 B-treatment
treatment 10 19 236 245 I-treatment
with 20 24 246 250 I-treatment
T 25 26 251 252 I-treatment
- 26 27 252 253 I-treatment
DM1 27 30 253 256 I-treatment
for 31 34 257 260 O
Cohorts 35 42 261 268 O
4A-4B 43 48 269 274 O

At 0 2 275 277 O
least 3 8 278 283 O
2 9 10 284 285 B-lower_bound
weeks 11 16 286 291 I-lower_bound
washout 17 24 292 299 O
period 25 31 300 306 O
post 32 36 307 311 B-treatment
chemotherapy 37 49 312 324 I-treatment
, 49 50 324 325 O
any 51 54 326 329 O
prior 55 60 330 335 B-treatment
protocol 61 69 336 344 I-treatment
therapy 70 77 345 352 I-treatment
, 77 78 352 353 O
lapatinib 79 88 354 363 B-treatment
, 88 89 363 364 O
other 90 95 365 370 O
targeted 96 104 371 379 B-treatment
or 105 107 380 382 O
biologic 108 116 383 391 B-treatment
therapy 117 124 392 399 I-treatment
, 124 125 399 400 O
or 126 128 401 403 O
radiation 129 138 404 413 B-treatment
therapy 139 146 414 421 I-treatment
is 147 149 422 424 O
required 150 158 425 433 O
prior 159 164 434 439 O
to 165 167 440 442 O
study 168 173 443 448 O
entry 174 179 449 454 O

Cohort 0 6 455 461 O
3a 7 9 462 464 O
will 10 14 465 469 O
have 15 19 470 474 O
participants 20 32 475 487 O
with 33 37 488 492 O
no 38 40 493 495 O
prior 41 46 496 501 B-treatment
lapatinib 47 56 502 511 I-treatment
therapy 57 64 512 519 I-treatment

Cohort 0 6 520 526 O
3b 7 9 527 529 O
will 10 14 530 534 O
have 15 19 535 539 O
had 20 23 540 543 O
prior 24 29 544 549 B-treatment
lapatinib 30 39 550 559 I-treatment
therapy 40 47 560 567 I-treatment

Cohort 0 6 568 574 O
4a 7 9 575 577 O
will 10 14 578 582 O
have 15 19 583 587 O
participants 20 32 588 600 O
with 33 37 601 605 O
previously 38 48 606 616 O
untreated 49 58 617 626 O
brain 59 64 627 632 B-cancer
metastases 65 75 633 643 I-cancer

Cohort 0 6 644 650 O
4b 7 9 651 653 O
will 10 14 654 658 O
have 15 19 659 663 O
participants 20 32 664 676 O
with 33 37 677 681 O
progressive 38 49 682 693 O
brain 50 55 694 699 B-cancer
metastases 56 66 700 710 I-cancer

Cohort 0 6 711 717 O
4c 7 9 718 720 O
will 10 14 721 725 O
have 15 19 726 730 O
participants 20 32 731 743 O
will 33 37 744 748 O
have 38 42 749 753 O
progressive 43 54 754 765 O
brain 55 60 766 771 B-treatment
metastases 61 71 772 782 I-treatment
and 72 75 783 786 O
prior 76 81 787 792 B-treatment
T 82 83 793 794 I-treatment
- 83 84 794 795 I-treatment
DM1 84 87 795 798 I-treatment

Concurrent 0 10 799 809 O
use 11 14 810 813 O
of 15 17 814 816 O
enzyme 18 24 817 823 B-treatment
- 24 25 823 824 I-treatment
inducing 25 33 824 832 I-treatment
antiepileptic 34 47 833 846 I-treatment
drugs 48 53 847 852 I-treatment
( 54 55 853 854 I-treatment
EIAEDs 55 61 854 860 I-treatment
) 61 62 860 861 I-treatment
, 62 63 861 862 O
including 64 73 863 872 O
phenytoin 74 83 873 882 B-treatment
, 83 84 882 883 O
carbamazepine 85 98 884 897 B-treatment
, 98 99 897 898 O
oxcarbazepine 100 113 899 912 B-treatment
, 113 114 912 913 O
fosphenytoin 115 127 914 926 B-treatment
, 127 128 926 927 O
phenobarbital 129 142 928 941 B-treatment
, 142 143 941 942 O
pentobarbital 144 157 943 956 B-treatment
, 157 158 956 957 O
or 159 161 958 960 O
primidone 162 171 961 970 B-treatment

For 0 3 971 974 O
Cohorts 4 11 975 982 O
4A 12 14 983 985 O
, 14 15 985 986 O
4B 16 18 987 989 O
, 18 19 989 990 O
and 20 23 991 994 O
4C 24 26 995 997 O
: 26 27 997 998 O
Patients 28 36 999 1007 O
with 37 41 1008 1012 O
myocardial 42 52 1013 1023 B-chronic_disease
infarction 53 63 1024 1034 I-chronic_disease
or 64 66 1035 1037 O
cardiomyopathy 67 81 1038 1052 B-chronic_disease
onset 82 87 1053 1058 O
within 88 94 1059 1065 O
the 95 98 1066 1069 O
last 99 103 1070 1074 B-upper_bound
6 104 105 1075 1076 I-upper_bound
months 106 112 1077 1083 I-upper_bound
are 113 116 1084 1087 O
excluded 117 125 1088 1096 O

For 0 3 1097 1100 O
cohort 4 10 1101 1107 O
1 11 12 1108 1109 O
, 12 13 1109 1110 O
patients 14 22 1111 1119 O
must 23 27 1120 1124 O
have 28 32 1125 1129 O
new 33 36 1130 1133 O
or 37 39 1134 1136 O
progressive 40 51 1137 1148 O
CNS 52 55 1149 1152 B-cancer
lesions 56 63 1153 1160 I-cancer
, 63 64 1160 1161 O
as 65 67 1162 1164 O
assessed 68 76 1165 1173 O
by 77 79 1174 1176 O
the 80 83 1177 1180 O
patient 84 91 1181 1188 O
's 91 93 1188 1190 O
treating 94 102 1191 1199 O
physician 103 112 1200 1209 O

For 0 3 1210 1213 O
patients 4 12 1214 1222 O
who 13 16 1223 1226 O
undergo 17 24 1227 1234 O
surgery 25 32 1235 1242 B-treatment
, 32 33 1242 1243 O
postoperative 34 47 1244 1257 O
whole 48 53 1258 1263 B-treatment
brain 54 59 1264 1269 I-treatment
radiation 60 69 1270 1279 I-treatment
therapy 70 77 1280 1287 I-treatment
will 78 82 1288 1292 O
not 83 86 1293 1296 O
be 87 89 1297 1299 O
allowed 90 97 1300 1307 O
while 98 103 1308 1313 O
patients 104 112 1314 1322 O
are 113 116 1323 1326 O
on 117 119 1327 1329 O
study 120 125 1330 1335 O
( 126 127 1336 1337 O
concurrent 127 137 1337 1347 O
neratinib 138 147 1348 1357 B-treatment
and 148 151 1358 1361 O
radiation 152 161 1362 1371 O
therapy 162 169 1372 1379 O
has 170 173 1380 1383 O
not 174 177 1384 1387 O
been 178 182 1388 1392 O
studied 183 190 1393 1400 O
and 191 194 1401 1404 O
toxicity 195 203 1405 1413 O
of 204 206 1414 1416 O
this 207 211 1417 1421 O
is 212 214 1422 1424 O
unknown 215 222 1425 1432 O
) 222 223 1432 1433 O

HER2 0 4 1434 1438 B-clinical_variable
gene 5 9 1439 1443 I-clinical_variable
amplification 10 23 1444 1457 I-clinical_variable
( 24 25 1458 1459 O
> 25 26 1459 1460 O
6 27 28 1461 1462 B-lower_bound
HER2 29 33 1463 1467 I-lower_bound
gene 34 38 1468 1472 I-lower_bound
copies 39 45 1473 1479 I-lower_bound
per 46 49 1480 1483 I-lower_bound
nucleus 50 57 1484 1491 I-lower_bound
or 58 60 1492 1494 O
a 61 62 1495 1496 O
FISH 63 67 1497 1501 B-clinical_variable
ratio 68 73 1502 1507 I-clinical_variable
[ 74 75 1508 1509 I-clinical_variable
HER2 75 79 1509 1513 I-clinical_variable
gene 80 84 1514 1518 I-clinical_variable
copies 85 91 1519 1525 I-clinical_variable
to 92 94 1526 1528 I-clinical_variable
chromosome 95 105 1529 1539 I-clinical_variable
17 106 108 1540 1542 I-clinical_variable
signals 109 116 1543 1550 I-clinical_variable
] 116 117 1550 1551 I-clinical_variable
of 118 120 1552 1554 O
≥ 121 122 1555 1556 O
2.0 123 126 1557 1560 B-lower_bound
) 126 127 1560 1561 O

Head 0 4 1562 1566 B-treatment
CT 5 7 1567 1569 I-treatment
with 8 12 1570 1574 O
contrast 13 21 1575 1583 O
is 22 24 1584 1586 O
allowed 25 32 1587 1594 O
in 33 35 1595 1597 O
place 36 41 1598 1603 O
of 42 44 1604 1606 O
MRI 45 48 1607 1610 B-treatment
at 49 51 1611 1613 O
baseline 52 60 1614 1622 O
and 61 64 1623 1626 O
throughout 65 75 1627 1637 O
the 76 79 1638 1641 O
study 80 85 1642 1647 O
if 86 88 1648 1650 O
MRI 89 92 1651 1654 O
is 93 95 1655 1657 O
contraindicated 96 111 1658 1673 O
and 112 115 1674 1677 O
a 116 117 1678 1679 O
participant 118 129 1680 1691 O
's 129 131 1691 1693 O
CNS 132 135 1694 1697 B-chronic_disease
lesions 136 143 1698 1705 I-chronic_disease
are 144 147 1706 1709 O
clearly 148 155 1710 1717 O
measurable 156 166 1718 1728 O
on 167 169 1729 1731 O
the 170 173 1732 1735 O
head 174 178 1736 1740 B-treatment
CT 179 181 1741 1743 I-treatment

History 0 7 1744 1751 O
of 8 10 1752 1754 O
allergic 11 19 1755 1763 O
reactions 20 29 1764 1773 O
attributed 30 40 1774 1784 O
to 41 43 1785 1787 O
compounds 44 53 1788 1797 O
of 54 56 1798 1800 O
similar 57 64 1801 1808 O
chemical 65 73 1809 1817 O
or 74 76 1818 1820 O
biologic 77 85 1821 1829 O
composition 86 97 1830 1841 O
to 98 100 1842 1844 O
neratinib 101 110 1845 1854 B-allergy_name

History 0 7 1855 1862 O
of 8 10 1863 1865 O
severe 11 17 1866 1872 O
allergic 18 26 1873 1881 O
reactions 27 36 1882 1891 O
or 37 39 1892 1894 O
intolerability 40 54 1895 1909 O
attributed 55 65 1910 1920 O
to 66 68 1921 1923 O
compounds 69 78 1924 1933 O
of 79 81 1934 1936 O
similar 82 89 1937 1944 O
chemical 90 98 1945 1953 O
or 99 101 1954 1956 O
biologic 102 110 1957 1965 O
composition 111 122 1966 1977 O
to 123 125 1978 1980 O
neratinib 126 135 1981 1990 B-allergy_name
and 136 139 1991 1994 O
T 140 141 1995 1996 B-allergy_name
- 141 142 1996 1997 I-allergy_name
DM1 142 145 1997 2000 I-allergy_name
for 146 149 2001 2004 O
Cohorts 150 157 2005 2012 O
4A-4C 158 163 2013 2018 O
Concurrent 164 174 2019 2029 O
use 175 178 2030 2033 O
of 179 181 2034 2036 O
enzyme 182 188 2037 2043 B-allergy_name
- 188 189 2043 2044 I-allergy_name
inducing 189 197 2044 2052 I-allergy_name
antiepileptic 198 211 2053 2066 I-allergy_name
drugs 212 217 2067 2072 I-allergy_name
( 218 219 2073 2074 I-allergy_name
EIAEDs 219 225 2074 2080 I-allergy_name
) 225 226 2080 2081 I-allergy_name
, 226 227 2081 2082 O
including 228 237 2083 2092 O
phenytoin 238 247 2093 2102 B-allergy_name
, 247 248 2102 2103 O
carbamazepine 249 262 2104 2117 B-allergy_name
, 262 263 2117 2118 O
oxcarbazepine 264 277 2119 2132 B-allergy_name
, 277 278 2132 2133 O
fosphenytoin 279 291 2134 2146 B-allergy_name
, 291 292 2146 2147 O
phenobarbital 293 306 2148 2161 B-allergy_name
, 306 307 2161 2162 O
pentobarbital 308 321 2163 2176 B-allergy_name
, 321 322 2176 2177 O
or 323 325 2178 2180 O
primidone 326 335 2181 2190 B-allergy_name

In 0 2 2191 2193 O
cohort 3 9 2194 2200 O
1 10 11 2201 2202 O
, 11 12 2202 2203 O
patients 13 21 2204 2212 O
must 22 26 2213 2217 O
have 27 31 2218 2222 O
measurable 32 42 2223 2233 O
CNS 43 46 2234 2237 B-chronic_disease
disease 47 54 2238 2245 I-chronic_disease
, 54 55 2245 2246 O
defined 56 63 2247 2254 O
as 64 66 2255 2257 O
at 67 69 2258 2260 O
least 70 75 2261 2266 O
one 76 79 2267 2270 B-lower_bound
parenchymal 80 91 2271 2282 O
brain 92 97 2283 2288 O
lesion 98 104 2289 2295 O
that 105 109 2296 2300 O
can 110 113 2301 2304 O
be 114 116 2305 2307 O
accurately 117 127 2308 2318 O
measured 128 136 2319 2327 O
in 137 139 2328 2330 O
at 140 142 2331 2333 O
least 143 148 2334 2339 O
one 149 152 2340 2343 O
dimension 153 162 2344 2353 B-clinical_variable
with 163 167 2354 2358 O
longest 168 175 2359 2366 O
dimension 176 185 2367 2376 O
≥10 186 189 2377 2380 O
mm 190 192 2381 2383 I-lower_bound
by 193 195 2384 2386 O
local 196 201 2387 2392 O
radiology 202 211 2393 2402 O
review 212 218 2403 2409 O

In 0 2 2410 2412 O
cohort 3 9 2413 2419 O
2 10 11 2420 2421 O
, 11 12 2421 2422 O
eligible 13 21 2423 2431 O
patients 22 30 2432 2440 O
will 31 35 2441 2445 O
include 36 43 2446 2453 O
those 44 49 2454 2459 O
who 50 53 2460 2463 O
have 54 58 2464 2468 O
CNS 59 62 2469 2472 B-chronic_disease
disease 63 70 2473 2480 I-chronic_disease
that 71 75 2481 2485 O
is 76 78 2486 2488 O
amenable 79 87 2489 2497 O
for 88 91 2498 2501 O
surgery 92 99 2502 2509 B-treatment
( 100 101 2510 2511 O
typically 101 110 2511 2520 O
< 111 112 2521 2522 O
3 113 114 2523 2524 B-upper_bound
brain 115 120 2525 2530 B-clinical_variable
metastases 121 131 2531 2541 I-clinical_variable
and 132 135 2542 2545 O
with 136 140 2546 2550 O
planned 141 148 2551 2558 O
resection 149 158 2559 2568 O
by 159 161 2569 2571 O
neurosurgery 162 174 2572 2584 B-treatment
) 174 175 2584 2585 O

In 0 2 2586 2588 O
cohort 3 9 2589 2595 O
3 10 11 2596 2597 O
, 11 12 2597 2598 O
eligible 13 21 2599 2607 O
patients 22 30 2608 2616 O
must 31 35 2617 2621 O
have 36 40 2622 2626 O
measurable 41 51 2627 2637 O
Central 52 59 2638 2645 B-chronic_disease
Nervous 60 67 2646 2653 I-chronic_disease
System 68 74 2654 2660 I-chronic_disease
disease 75 82 2661 2668 I-chronic_disease

In 0 2 2669 2671 O
cohort 3 9 2672 2678 O
4 10 11 2679 2680 O
, 11 12 2680 2681 O
eligible 13 21 2682 2690 O
patients 22 30 2691 2699 O
must 31 35 2700 2704 O
have 36 40 2705 2709 O
measurable 41 51 2710 2720 O
Central 52 59 2721 2728 B-chronic_disease
Nervous 60 67 2729 2736 I-chronic_disease
System 68 74 2737 2743 I-chronic_disease
disease 75 82 2744 2751 I-chronic_disease

Individuals 0 11 2752 2763 O
with 12 16 2764 2768 O
a 17 18 2769 2770 O
history 19 26 2771 2778 O
of 27 29 2779 2781 O
a 30 31 2782 2783 O
different 32 41 2784 2793 O
active 42 48 2794 2800 O
malignancy 49 59 2801 2811 B-cancer

Invasive 0 8 2812 2820 O
primary 9 16 2821 2828 B-cancer
tumor 17 22 2829 2834 I-cancer
or 23 25 2835 2837 O
metastatic 26 36 2838 2848 B-cancer
tissue 37 43 2849 2855 O
confirmation 44 56 2856 2868 O
of 57 59 2869 2871 O
HER2 60 64 2872 2876 O
- 64 65 2876 2877 O
positive 65 73 2877 2885 O
status 74 80 2886 2892 O

It 0 2 2893 2895 O
is 3 5 2896 2898 O
anticipated 6 17 2899 2910 O
that 18 22 2911 2915 O
some 23 27 2916 2920 O
patients 28 36 2921 2929 O
may 37 40 2930 2933 O
have 41 45 2934 2938 O
multiple 46 54 2939 2947 O
progressive 55 66 2948 2959 O
CNS 67 70 2960 2963 O
lesions 71 78 2964 2971 O
, 78 79 2971 2972 O
one 80 83 2973 2976 O
or 84 86 2977 2979 O
several 87 94 2980 2987 O
of 95 97 2988 2990 O
which 98 103 2991 2996 O
are 104 107 2997 3000 O
treated 108 115 3001 3008 O
with 116 120 3009 3013 O
SRS 121 124 3014 3017 B-treatment
or 125 127 3018 3020 O
surgery 128 135 3021 3028 B-treatment
with 136 140 3029 3033 O
residual 141 149 3034 3042 O
untreated 150 159 3043 3052 O
lesions 160 167 3053 3060 O
remaining 168 177 3061 3070 O

It 0 2 3071 3073 O
is 3 5 3074 3076 O
anticipated 6 17 3077 3088 O
that 18 22 3089 3093 O
that 23 27 3094 3098 O
patients 28 36 3099 3107 O
who 37 40 3108 3111 O
have 41 45 3112 3116 O
intracranial 46 58 3117 3129 B-chronic_disease
disease 59 66 3130 3137 I-chronic_disease
amenable 67 75 3138 3146 O
to 76 78 3147 3149 O
surgery 79 86 3150 3157 B-treatment
will 87 91 3158 3162 O
have 92 96 3163 3167 O
measurable 97 107 3168 3178 O
CNS 108 111 3179 3182 B-chronic_disease
disease 112 119 3183 3190 I-chronic_disease
prior 120 125 3191 3196 O
to 126 128 3197 3199 O
study 129 134 3200 3205 O
entry 135 140 3206 3211 O
and 141 144 3212 3215 O
to 145 147 3216 3218 O
resection 148 157 3219 3228 B-treatment

Lung 0 4 3229 3233 B-chronic_disease
disease 5 12 3234 3241 I-chronic_disease
from 13 17 3242 3246 O
etiology 18 26 3247 3255 O
other 27 32 3256 3261 O
than 33 37 3262 3266 O
metastatic 38 48 3267 3277 B-cancer
breast 49 55 3278 3284 I-cancer
cancer 56 62 3285 3291 I-cancer
resulting 63 72 3292 3301 O
in 73 75 3302 3304 O
dyspnea 76 83 3305 3312 B-chronic_disease
at 84 86 3313 3315 O
rest 87 91 3316 3320 O
( 92 93 3321 3322 O
4A-4C 93 98 3322 3327 O
) 98 99 3327 3328 O

More 0 4 3329 3333 O
than 5 9 3334 3338 O
two 10 13 3339 3342 B-lower_bound
seizures 14 22 3343 3351 B-chronic_disease
over 23 27 3352 3356 O
the 28 31 3357 3360 O
last 32 36 3361 3365 B-upper_bound
4 37 38 3366 3367 I-upper_bound
weeks 39 44 3368 3373 I-upper_bound
prior 45 50 3374 3379 I-upper_bound
to 51 53 3380 3382 O
study 54 59 3383 3388 O
entry 60 65 3389 3394 O

No 0 2 3395 3397 O
increase 3 11 3398 3406 O
in 12 14 3407 3409 O
corticosteroid 15 29 3410 3424 B-treatment
dose 30 34 3425 3429 O
in 35 37 3430 3432 O
the 38 41 3433 3436 O
week 42 46 3437 3441 O
prior 47 52 3442 3447 O
to 53 55 3448 3450 O
baseline 56 64 3451 3459 O
brain 65 70 3460 3465 B-treatment
MRI 71 74 3466 3469 I-treatment

No 0 2 3470 3472 O
prior 3 8 3473 3478 B-treatment
therapy 9 16 3479 3486 I-treatment
with 17 21 3487 3491 I-treatment
neratinib 22 31 3492 3501 I-treatment

No 0 2 3502 3504 O
washout 3 10 3505 3512 O
is 11 13 3513 3515 O
required 14 22 3516 3524 O
for 23 26 3525 3528 O
hormonal 27 35 3529 3537 B-treatment
therapy 36 43 3538 3545 I-treatment

Not 0 3 3546 3549 B-pregnancy
pregnant 4 12 3550 3558 I-pregnancy
or 13 15 3559 3561 O
breastfeeding 16 29 3562 3575 O

Over 0 4 3576 3580 O
- 4 5 3580 3581 O
expression 5 15 3581 3591 O
by 16 18 3592 3594 O
immunohistochemistry 19 39 3595 3615 B-clinical_variable
( 40 41 3616 3617 I-clinical_variable
IHC 41 44 3617 3620 I-clinical_variable
) 44 45 3620 3621 I-clinical_variable
with 46 50 3622 3626 O
score 51 56 3627 3632 O
of 57 59 3633 3635 O
3 60 61 3636 3637 O
+ 61 62 3637 3638 O
( 63 64 3639 3640 O
in 64 66 3640 3642 O
> 67 68 3643 3644 O
30 69 71 3645 3647 B-lower_bound
% 71 72 3647 3648 I-lower_bound
of 73 75 3649 3651 O
invasive 76 84 3652 3660 O
tumor 85 90 3661 3666 B-cancer
cells 91 96 3667 3672 O
) 96 97 3672 3673 O

Participants 0 12 3674 3686 O
who 13 16 3687 3690 O
are 17 20 3691 3694 O
currently 21 30 3695 3704 O
receiving 31 40 3705 3714 O
any 41 44 3715 3718 O
other 45 50 3719 3724 O
investigational 51 66 3725 3740 B-treatment
agents 67 73 3741 3747 I-treatment

Participants 0 12 3748 3760 O
who 13 16 3761 3764 O
have 17 21 3765 3769 O
had 22 25 3770 3773 O
chemotherapy 26 38 3774 3786 B-treatment
or 39 41 3787 3789 O
radiotherapy 42 54 3790 3802 B-treatment
( 55 56 3803 3804 O
including 56 65 3804 3813 O
investigational 66 81 3814 3829 B-treatment
agents 82 88 3830 3836 I-treatment
) 88 89 3836 3837 O
within 90 96 3838 3844 O
2 97 98 3845 3846 B-upper_bound
weeks 99 104 3847 3852 I-upper_bound
prior 105 110 3853 3858 I-upper_bound
to 111 113 3859 3861 O
entering 114 122 3862 3870 O
the 123 126 3871 3874 O
study 127 132 3875 3880 O
or 133 135 3881 3883 O
those 136 141 3884 3889 O
who 142 145 3890 3893 O
have 146 150 3894 3898 O
not 151 154 3899 3902 O
recovered 155 164 3903 3912 O
adequately 165 175 3913 3923 O
from 176 180 3924 3928 O
adverse 181 188 3929 3936 O
events 189 195 3937 3943 O
due 196 199 3944 3947 O
to 200 202 3948 3950 O
agents 203 209 3951 3957 O
administered 210 222 3958 3970 O
more 223 227 3971 3975 O
than 228 232 3976 3980 O
4 233 234 3981 3982 B-lower_bound
weeks 235 240 3983 3988 I-lower_bound
earlier 241 248 3989 3996 O

Patients 0 8 3997 4005 O
( 9 10 4006 4007 O
men 10 13 4007 4010 B-gender
or 14 16 4011 4013 O
women 17 22 4014 4019 B-gender
) 22 23 4019 4020 O
must 24 28 4021 4025 O
have 29 33 4026 4030 O
histologically 34 48 4031 4045 O
or 49 51 4046 4048 O
cytologically 52 65 4049 4062 O
confirmed 66 75 4063 4072 O
invasive 76 84 4073 4081 B-cancer
breast 85 91 4082 4088 I-cancer
cancer 92 98 4089 4095 I-cancer
, 98 99 4095 4096 O
with 100 104 4097 4101 O
metastatic 105 115 4102 4112 B-cancer
disease 116 123 4113 4120 I-cancer

Patients 0 8 4121 4129 O
who 9 12 4130 4133 O
are 13 16 4134 4137 O
receiving 17 26 4138 4147 O
any 27 30 4148 4151 O
cancer 31 37 4152 4158 B-treatment
- 37 38 4158 4159 I-treatment
directed 38 46 4159 4167 I-treatment
concurrent 47 57 4168 4178 I-treatment
therapy 58 65 4179 4186 I-treatment
, 65 66 4186 4187 O
such 67 71 4188 4192 O
as 72 74 4193 4195 O
concurrent 75 85 4196 4206 O
chemotherapy 86 98 4207 4219 B-treatment
, 98 99 4219 4220 O
radiotherapy 100 112 4221 4233 B-treatment
, 112 113 4233 4234 O
or 114 116 4235 4237 O
hormonal 117 125 4238 4246 B-treatment
therapy 126 133 4247 4254 I-treatment
while 134 139 4255 4260 O
on 140 142 4261 4263 O
study 143 148 4264 4269 O
. 148 149 4269 4270 O
Concurrent 150 160 4271 4281 O
treatment 161 170 4282 4291 B-treatment
with 171 175 4292 4296 O
bisphosphonates 176 191 4297 4312 B-treatment
and 192 195 4313 4316 O
denosumab 196 205 4317 4326 B-treatment
is 206 208 4327 4329 O
allowed 209 216 4330 4337 O
for 217 220 4338 4341 O
bony 221 225 4342 4346 O
metastases 226 236 4347 4357 B-cancer
but 237 240 4358 4361 O
should 241 247 4362 4368 O
be 248 250 4369 4371 O
started 251 258 4372 4379 O
before 259 265 4380 4386 O
the 266 269 4387 4390 O
first 270 275 4391 4396 O
dose 276 280 4397 4401 O
of 281 283 4402 4404 O
neratinib 284 293 4405 4414 B-treatment

Patients 0 8 4415 4423 O
who 9 12 4424 4427 O
are 13 16 4428 4431 O
receiving 17 26 4432 4441 O
any 27 30 4442 4445 O
cancer 31 37 4446 4452 B-treatment
- 37 38 4452 4453 I-treatment
directed 38 46 4453 4461 I-treatment
concurrent 47 57 4462 4472 I-treatment
therapy 58 65 4473 4480 I-treatment
, 65 66 4480 4481 O
such 67 71 4482 4486 O
as 72 74 4487 4489 O
concurrent 75 85 4490 4500 B-treatment
chemotherapy 86 98 4501 4513 I-treatment
, 98 99 4513 4514 O
radiotherapy 100 112 4515 4527 B-treatment
, 112 113 4527 4528 O
or 114 116 4529 4531 O
hormonal 117 125 4532 4540 B-treatment
therapy 126 133 4541 4548 I-treatment
while 134 139 4549 4554 O
on 140 142 4555 4557 O
study 143 148 4558 4563 O
. 148 149 4563 4564 O
Concurrent 150 160 4565 4575 B-treatment
treatment 161 170 4576 4585 I-treatment
with 171 175 4586 4590 I-treatment
bisphosphonates 176 191 4591 4606 I-treatment
is 192 194 4607 4609 O
allowed 195 202 4610 4617 O
but 203 206 4618 4621 O
should 207 213 4622 4628 O
be 214 216 4629 4631 O
started 217 224 4632 4639 O
before 225 231 4640 4646 O
the 232 235 4647 4650 O
first 236 241 4651 4656 O
dose 242 246 4657 4661 O
of 247 249 4662 4664 O
neratinib 250 259 4665 4674 B-treatment

Patients 0 8 4675 4683 O
who 9 12 4684 4687 O
have 13 17 4688 4692 O
had 18 21 4693 4696 O
prior 22 27 4697 4702 B-treatment
WBRT 28 32 4703 4707 I-treatment
and/or 33 39 4708 4714 O
SRS 40 43 4715 4718 B-treatment
and 44 47 4719 4722 O
then 48 52 4723 4727 O
whose 53 58 4728 4733 O
prior 59 64 4734 4739 O
treated 65 72 4740 4747 O
lesions 73 80 4748 4755 B-cancer
have 81 85 4756 4760 O
progressed 86 96 4761 4771 O
thereafter 97 107 4772 4782 O

Patients 0 8 4783 4791 O
who 9 12 4792 4795 O
have 13 17 4796 4800 O
had 18 21 4801 4804 O
prior 22 27 4805 4810 B-treatment
cranial 28 35 4811 4818 I-treatment
surgery 36 43 4819 4826 I-treatment
are 44 47 4827 4830 O
eligible 48 56 4831 4839 O
, 56 57 4839 4840 O
provided 58 66 4841 4849 O
that 67 71 4850 4854 O
there 72 77 4855 4860 O
is 78 80 4861 4863 O
evidence 81 89 4864 4872 O
of 90 92 4873 4875 O
measurable 93 103 4876 4886 O
residual 104 112 4887 4895 O
or 113 115 4896 4898 O
progressive 116 127 4899 4910 O
lesions 128 135 4911 4918 O
, 135 136 4918 4919 O
and 137 140 4920 4923 O
at 141 143 4924 4926 O
least 144 149 4927 4932 O
2 150 151 4933 4934 B-lower_bound
weeks 152 157 4935 4940 I-lower_bound
have 158 162 4941 4945 O
passed 163 169 4946 4952 O
since 170 175 4953 4958 O
surgery 176 183 4959 4966 O

Patients 0 8 4967 4975 O
with 9 13 4976 4980 O
a 14 15 4981 4982 O
negative 16 24 4983 4991 O
or 25 27 4992 4994 O
equivocal 28 37 4995 5004 O
overall 38 45 5005 5012 O
result 46 52 5013 5019 O
( 53 54 5020 5021 O
FISH 54 58 5021 5025 B-clinical_variable
ratio 59 64 5026 5031 O
of 65 67 5032 5034 O
< 68 69 5035 5036 O
2.0 70 73 5037 5040 B-upper_bound
or 74 76 5041 5043 O
≤ 77 78 5044 5045 O
6.0 79 82 5046 5049 B-upper_bound
HER2 83 87 5050 5054 B-clinical_variable
gene 88 92 5055 5059 O
copies 93 99 5060 5066 O
per 100 103 5067 5070 O
nucleus 104 111 5071 5078 O
) 111 112 5078 5079 O
and 113 116 5080 5083 O
IHC 117 120 5084 5087 B-clinical_variable
staining 121 129 5088 5096 O
scores 130 136 5097 5103 O
of 137 139 5104 5106 O
0 140 141 5107 5108 O
, 141 142 5108 5109 O
1 143 144 5110 5111 O
+ 144 145 5111 5112 O
, 145 146 5112 5113 O
2 147 148 5114 5115 B-upper_bound
+ 148 149 5115 5116 I-upper_bound
are 150 153 5117 5120 O
not 154 157 5121 5124 O
eligible 158 166 5125 5133 O
for 167 170 5134 5137 O
enrollment 171 181 5138 5148 O

Patients 0 8 5149 5157 O
with 9 13 5158 5162 O
known 14 19 5163 5168 O
contraindication 20 36 5169 5185 O
to 37 39 5186 5188 O
MRI 40 43 5189 5192 B-treatment
, 43 44 5192 5193 O
such 45 49 5194 5198 O
as 50 52 5199 5201 O
cardiac 53 60 5202 5209 O
pacemaker 61 70 5210 5219 B-treatment
, 70 71 5219 5220 O
shrapnel 72 80 5221 5229 B-treatment
, 80 81 5229 5230 O
or 82 84 5231 5233 O
ocular 85 91 5234 5240 O
foreign 92 99 5241 5248 O
body 100 104 5249 5253 O

Patients 0 8 5254 5262 O
with 9 13 5263 5267 O
progressive 14 25 5268 5279 B-chronic_disease
disease 26 33 5280 5287 I-chronic_disease
( 34 35 5288 5289 O
Cohort 35 41 5289 5295 O
1 42 43 5296 5297 O
) 43 44 5297 5298 O

Patients 0 8 5299 5307 O
without 9 16 5308 5315 O
pathologic 17 27 5316 5326 O
or 28 30 5327 5329 O
cytologic 31 40 5330 5339 O
confirmation 41 53 5340 5352 O
of 54 56 5353 5355 O
metastatic 57 67 5356 5366 B-cancer
disease 68 75 5367 5374 I-cancer
should 76 82 5375 5381 O
have 83 87 5382 5386 O
unequivocal 88 99 5387 5398 O
evidence 100 108 5399 5407 O
of 109 111 5408 5410 O
metastasis 112 122 5411 5421 B-cancer
by 123 125 5422 5424 O
physical 126 134 5425 5433 O
exam 135 139 5434 5438 O
or 140 142 5439 5441 O
radiologic 143 153 5442 5452 B-treatment
study 154 159 5453 5458 I-treatment

Pregnant 0 8 5459 5467 B-pregnancy
women 9 14 5468 5473 B-gender

Prior 0 5 5474 5479 B-treatment
trastuzumab 6 17 5480 5491 I-treatment
and 18 21 5492 5495 O
lapatinib 22 31 5496 5505 B-treatment
therapy 32 39 5506 5513 I-treatment

Significant 0 11 5514 5525 O
malabsorption 12 25 5526 5539 B-chronic_disease
syndrome 26 34 5540 5548 I-chronic_disease
or 35 37 5549 5551 O
inability 38 47 5552 5561 O
to 48 50 5562 5564 O
tolerate 51 59 5565 5573 O
oral 60 64 5574 5578 O
medications 65 76 5579 5590 B-treatment

Such 0 4 5591 5595 O
patients 5 13 5596 5604 O
are 14 17 5605 5608 O
eligible 18 26 5609 5617 O
for 27 30 5618 5621 O
enrollment 31 41 5622 5632 O
on 42 44 5633 5635 O
this 45 49 5636 5640 O
study 50 55 5641 5646 O
providing 56 65 5647 5656 O
that 66 70 5657 5661 O
at 71 73 5662 5664 O
least 74 79 5665 5670 O
one 80 83 5671 5674 B-lower_bound
residual 84 92 5675 5683 O
( 93 94 5684 5685 O
i.e. 94 98 5685 5689 O
non 99 102 5690 5693 B-treatment
- 102 103 5693 5694 I-treatment
SRS 103 106 5694 5697 I-treatment
- 106 107 5697 5698 O
treated 107 114 5698 5705 O
or 115 117 5706 5708 O
non 118 121 5709 5712 B-treatment
- 121 122 5712 5713 I-treatment
resected 122 130 5713 5721 I-treatment
) 130 131 5721 5722 O
lesion 132 138 5723 5729 O
is 139 141 5730 5732 O
measurable 142 152 5733 5743 O
( 153 154 5744 5745 O
≥10 154 157 5745 5748 O
mm 158 160 5749 5751 I-lower_bound
) 160 161 5751 5752 O

There 0 5 5753 5758 O
is 6 8 5759 5761 O
no 9 11 5762 5764 O
limit 12 17 5765 5770 O
to 18 20 5771 5773 O
the 21 24 5774 5777 O
number 25 31 5778 5784 O
of 32 34 5785 5787 O
previous 35 43 5788 5796 B-treatment
lines 44 49 5797 5802 I-treatment
of 50 52 5803 5805 I-treatment
therapy 53 60 5806 5813 I-treatment
( 61 62 5814 5815 O
including 62 71 5815 5824 O
chemotherapy 72 84 5825 5837 B-treatment
, 84 85 5837 5838 O
trastuzumab 86 97 5839 5850 B-treatment
, 97 98 5850 5851 O
and 99 102 5852 5855 O
endocrine 103 112 5856 5865 B-treatment
therapies 113 122 5866 5875 I-treatment
) 122 123 5875 5876 O

These 0 5 5877 5882 O
patients 6 14 5883 5891 O
may 15 18 5892 5895 O
include 19 26 5896 5903 O
those 27 32 5904 5909 O
who 33 36 5910 5913 O
have 37 41 5914 5918 O
received 42 50 5919 5927 O
or 51 53 5928 5930 O
not 54 57 5931 5934 O
received 58 66 5935 5943 O
previous 67 75 5944 5952 B-treatment
treatment(s 76 87 5953 5964 I-treatment
) 87 88 5964 5965 I-treatment
for 89 92 5966 5969 O
their 93 98 5970 5975 O
CNS 99 102 5976 5979 O

Those 0 5 5980 5985 O
with 6 10 5986 5990 O
leptomeningeal 11 25 5991 6005 B-cancer
metastases 26 36 6006 6016 I-cancer
as 37 39 6017 6019 O
the 40 43 6020 6023 O
only 44 48 6024 6028 O
site 49 53 6029 6033 O
of 54 56 6034 6036 O
CNS 57 60 6037 6040 B-chronic_disease
disease 61 68 6041 6048 I-chronic_disease

Uncontrolled 0 12 6049 6061 O
intercurrent 13 25 6062 6074 B-chronic_disease
illness 26 33 6075 6082 I-chronic_disease
including 34 43 6083 6092 O
, 43 44 6092 6093 O
but 45 48 6094 6097 O
not 49 52 6098 6101 O
limited 53 60 6102 6109 O
to 61 63 6110 6112 O
ongoing 64 71 6113 6120 O
or 72 74 6121 6123 O
active 75 81 6124 6130 B-chronic_disease
infection 82 91 6131 6140 I-chronic_disease
, 91 92 6140 6141 O
symptomatic 93 104 6142 6153 O
congestive 105 115 6154 6164 B-chronic_disease
heart 116 121 6165 6170 I-chronic_disease
failure 122 129 6171 6178 I-chronic_disease
, 129 130 6178 6179 O
unstable 131 139 6180 6188 B-chronic_disease
angina 140 146 6189 6195 I-chronic_disease
pectoris 147 155 6196 6204 I-chronic_disease
, 155 156 6204 6205 O
cardiac 157 164 6206 6213 B-chronic_disease
arrhythmia 165 175 6214 6224 I-chronic_disease
, 175 176 6224 6225 O
or 177 179 6226 6228 O
psychiatric 180 191 6229 6240 B-chronic_disease
illness 192 199 6241 6248 I-chronic_disease
/ 199 200 6248 6249 I-chronic_disease
social 200 206 6249 6255 I-chronic_disease
situations 207 217 6256 6266 I-chronic_disease
that 218 222 6267 6271 O
would 223 228 6272 6277 O
limit 229 234 6278 6283 O
compliance 235 245 6284 6294 O
with 246 250 6295 6299 O
study 251 256 6300 6305 O
requirements 257 269 6306 6318 O

Washout 0 7 6319 6326 O
from 8 12 6327 6331 O
trastuzumab 13 24 6332 6343 B-treatment

Washout 0 7 6344 6351 O
from 8 12 6352 6356 O
trastuzumab 13 24 6357 6368 B-treatment
or 25 27 6369 6371 O
hormonal 28 36 6372 6380 B-treatment
therapy 37 44 6381 6388 I-treatment

alopecia 0 8 6389 6397 B-chronic_disease

concurrent 0 10 6398 6408 O
hormonal 11 19 6409 6417 B-treatment
therapy 20 27 6418 6425 I-treatment

